LP352 for children and adults with DEE
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests a medication called LP352 for children and adults with certain types of epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathies). It's for people who already completed a previous study of LP352 and may benefit from continued treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous LP352 study (LP352-301 or LP352-302) up to Visit 8.
- You must have a diagnosis of Dravet syndrome, Lennox-Gastaut syndrome, or another developmental and epileptic encephalopathy.
- You must weigh at least 10 kg (about 22 pounds).
- You cannot be pregnant, breastfeeding, or planning to become pregnant.
- You cannot be at risk for suicidal behavior or have severe depression, anorexia, or bulimia.
- You cannot use cannabis products that are not approved or contain high THC.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a newer, more detailed type of genetic testing (long-read genome sequencing) to look for the cause of severe childhood epilepsy and developmental delays when standard testing has found nothing. The goal is to find answers for families who have gone without a diagnosis.
This program lets people who have already finished a clinical trial of the study drug LP352 and are still getting benefit from it keep receiving it. It's designed for those with developmental epileptic encephalopathy (a type of epilepsy that starts in childhood and affects development).
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This trial tests an investigational medicine called CBD-OS for people with a type of severe epilepsy called developmental and epileptic encephalopathy (DEE). The study aims to see if this treatment is safe and helps control seizures.
This trial tests a new type of brain stimulation (adaptive deep brain stimulation) that adjusts in real time to stop seizures in children with Lennox-Gastaut syndrome. It's for children who haven't gotten enough help from medications and have frequent drop seizures.
This trial tests a new drug called BMB-101 for people with absence epilepsy (including Jeavons syndrome) or developmental epileptic encephalopathies (DEE) like Dravet or Lennox-Gastaut. It aims to see if the drug can reduce seizure frequency and is safe.
Hear when a new Developmental and Epileptic Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.